drugset / Trial / NCT00390520

Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

NCT00390520

Phase 3 Completed 28 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).

Timeline

Start
2006-09
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 100 mg